Eli Lilly at CTAD 2026
Nov 16–19, 2026 Boston, MA ~1.7k attendees Website
Eli Lilly takes part in 4 sessions at CTAD 2026 in Boston. Its program spans imaging, blood tests and new mechanisms, from hippocampal subfield volumes to atrophy-defined subtypes. Its work includes the phase 2 mevidalen trial and the link between p-tau217 blood tests and neuropathology at autopsy.
| Organization | CTAD 2026 Attendance |
|---|---|
Eli Lilly Indianapolis, Indiana | ◆Platinum Sponsor |
Global drugmaker behind donanemab (Kisunla), an anti-amyloid antibody for early Alzheimer's, and the tau PET tracer flortaucipir. | Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue |
Instantly find 20 buyers from Eli Lilly
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction